Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
By H. Heerspink, D. Zeeuw, L. Wie, B. Leslie, J. List. Diabetes, obesity and metabolism, 2013
767 citations recorded by the source corpus.
Sodium–glucose co‐transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have diuretic‐like physiologic effects, we compared dapagliflozin and hydrochlorothiazide (HCTZ) effects on 24‐h blood pressure (BP), body weight, plasma volume and glomerular filtration rate (GFR).
Subfields: Endocrinology, Diabetes and Metabolism, Nephrology, Surgery
View Paper: https://www.semanticscholar.org/paper/f4b538e6fc173489e53ea024f4efe28fec6ac051
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors (2020, background): “In a study comparing dapagliflozin and hydrochlorothiazide, for example, a reduction in plasma volume and increase in erythrocyte mass was observed with dapagliflozin but not with hydrochlorothiazide (23).”
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017, background): “Increased erythropoietin and a median 7% increase in red blood cell mass, measured with (51)Cr-labeled erythrocytes, were observed in a small study (n = 30) of the SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes (26).”
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis (2016, methodology): “who were receiving treatment with dapagliflozin (19) have shown that red blood cell mass (as measured by (51)Cr-”